Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

SHOCKING: 27 | Mind Blowing Facts

How companies can strengthen their workforces in an uncertain labor market

While tech layoffs make splashy headlines, other industries like health care, financial services, and education are eager to scoop up tech workers.

Chart of the Day: Eli Lilly - A Retail Investor Favorite

Chart of the Day: Eli Lilly - A Retail Investor Favorite

The Chart of the Day belongs to the pharmaceutical company Eli Lilly (LLY) . I found the stock by using Barchart's powerful screening functions to find stocks with the highest technical buy signals, highest Weighted Alpha, superior current momentum and having a Trend Seeker buy signal then used the Flipchart...

Stocks Fall on Chinese Economic Concerns and Wariness Ahead of Fed Chair Powell

Stocks Fall on Chinese Economic Concerns and Wariness Ahead of Fed Chair Powell

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is down -0.77%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.88%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.73%. U.S. stocks this morning are moderately lower. U.S. stocks...

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Markets Today: Stocks Slip on China Economic Concerns and Higher Bond Yields

Morning Markets September E-Mini S&P 500 futures (ESU2 3) this morning are down -0.33%, and Sep Nasdaq 100 E-Mini futures (NQU2 3) are down -0.28%. U.S. stock index futures this morning are moderately lower. Negative carry-over from a decline in Chinese stocks is weighing on U.S. stock index futures on...

Commentary: By avoiding funding Alzheimer’s research, the government is cutting seniors’ life spans

Millions of patients and their caregivers breathed a collective sigh of relief when drugmaker Eli Lilly recently announced its new experimental Alzheimer’s medication appears to slow cognitive decline by 35%. The Food and Drug Administration could approve the new treatment, donanemab, as soon as this year.

Chicago Tribune

New weekly obesity injection could help people rapidly shed body weight

The National Institute for Health and Care Excellence (Nice) is judging whether or not the jab would be a good use of NHS funds.

New once-a week injection helps people lose large amount of weight

The National Institute for Health and Care Excellence (Nice) is seeing whether the drug would be a good use of NHS funds

inkl

Read news from The Economist, FT, and more,
with one subscription

New obesity jab that sparked diabetes row in US could get NHS green light

New obesity jab that sparked diabetes row in US could get NHS green light

Tirzepatide is currently approved by regulators for type 2 diabetes – but may soon also be approved for obesity

The Independent UK

New Alzheimer’s drug: what you need to know about donanemab’s promising trial results

New Alzheimer’s drug: what you need to know about donanemab’s promising trial results

American pharmaceutical company Eli Lilly announced last week that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to the company, their experimental drug, donanemab, was shown in a late-stage trial to slow cognitive decline by 35%. While these results do sound promising, the full data…

The Conversation

New Alzheimer’s drug slows cognitive decline by a third

New Alzheimer’s drug slows cognitive decline by a third

A new Alzheimer's drug, 'donanemab', was found to clear amyloid plaques from the brains, and slow cognitive decline by about a third.

Pharma firm claims drug trial slows Alzheimer’s progression by 35 per cent

Pharma firm claims drug trial slows Alzheimer’s progression by 35 per cent

A new drug given to Alzheimer's patients slowed the disease's progress by 35 per cent, the latest trial has revealed.

World ‘on cusp of first generation of treatments for Alzheimer’s’

Almost half of those on donanemab had no clinical progression of disease at one year compared with 29% on a placebo, a study showed.

Evening Standard

World ‘on the cusp of first generation of treatments for Alzheimer’s’

World ‘on the cusp of first generation of treatments for Alzheimer’s’

THE world is “on the cusp of a first generation of treatments for Alzheimer’s disease”, experts have said, as a new drug was found to slow…

The National (Scotland)

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug ‘slows symptoms’

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug ‘slows symptoms’

New drug donanemab appears to slow decline associated with Alzheimer’s

The Independent UK

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

World ‘on cusp of first generation of treatments for Alzheimer’s’ as new drug found

Almost half of those on donanemab had no clinical progression of disease at one year compared to 29% on placebo, a study showed.

New weight loss drug helping people lose 2.5 stone is 'coming to the UK'

A weekly injection of tirzepatide has seen people with obesity and diabetes lose over 15 percent of their bodyweight.

The Independent UK

Weight loss jab that can help patients shed two-and-a-half stone set for UK approval

Tirzepatide could be given to patients with diabetes or heat disease

Markets Today: Stock Index Futures Climb on Meta’s Earnings

Morning Markets June E-Mini S&P 500 futures (ESM2 3) this morning are up +0.47%, and June Nasdaq 100 E-Mini futures (NQM2 3) are up +0.87%. U.S. stock index futures this morning are moderately higher. Strength in technology stocks is lifting the overall market this morning, with Meta Platforms up more...

Get all your
news in one place.

100's of premium titles.
One news app.

Eli Lilly releases more data for new obesity drug, moving toward fast-track approval

There's already a huge demand for existing weight-loss drugs, so the new medication is highly anticipated. Obesity affects an estimated 650 million adults globally.

The Guardian - UK

‘I skip meals to make my insulin last’: the cost of diabetes in the global south

The three firms that control the insulin market are to cut costs in the US, but elsewhere users can spend all their pay to get the life-saving drug

The biggest U.S. pharmaceutical companies are lowering insulin costs to save themselves money

So much for altruism.

Chicago Sun-Times

Anti-obesity drug demand expected to skyrocket, but will insurance cover the cost?

New weight loss drugs can cost more than $1,000 a month, but most health plans don’t cover them.

Novo Nordisk will cut some U.S. insulin prices by up to 75% starting next year

The Danish drugmaker's move follows a similar announcement by rival Eli Lilly earlier this month. More than 8 million Americans use insulin, according to the American Diabetes Association.

This Essential Medical Treatment Could Finally Become Affordable For Everyone

Pharmaceutical giant Eli Lilly is slashing the list prices for some of its most popular insulin products by 70 percent.

$35 for insulin? What to know about Eli Lilly’s price slash for the diabetic medicine

Eli Lilly plans to slash the cost of some of its most popular insulin drugs later this year for people with and without insurance, in a move that could make the lifesaving medication more affordable for some patients living with diabetes.

1 … 26 27 28 29

People

Charles Marshall

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Warner Bros Discovery

Dow Jones Industrials

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Alzheimer Disease

Places

418,055 stories

149,226 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play